China’s new cancer drug toripalimab is approved in the US but will cost 30 times more

South China Morning Post

29 November 2023 - In China, a single dose vial costs US$280 but in the US it will have a wholesale price of US$8,892.

A cancer drug developed by Chinese scientists and recently approved by the US FDA will cost over 30 times more in the US than in China, with two other Chinese cancer drugs set to experience similar price bumps in the US market.

However, even with the huge price mark-up in the US, the Chinese cancer drugs will still be priced significantly less than similar drugs sold in the US.

Read South China Morning Post article


Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , US , Pricing , Affordability